MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer-Trial in progress.

被引：0
|
作者：
Bekaii-Saab, Tanios S.
Van Cutsem, Eric
Tabernero, Josep
Siena, Salvatore
Yoshino, Takayuki
Nakamura, Yoshiaki
Raghav, Kanwal Pratap Singh
Cercek, Andrea
Heinemann, Volker
Adelberg, David E.
Ward, James Edward
Yang, Shan
Andre, Thierry
Strickler, John H.
机构：
[1] Mayo Clin, Scottsdale, AZ USA
[2] Univ Hosp Gasthuisberg, Leuven, Belgium
[3] Univ Leuven, Leuven, Belgium
[4] Vall DHebron Univ Hosp & Inst Oncol VHIO, Barcelona, Spain
[5] Grande Osped Metropolitano Niguarda, Milan, Italy
[6] Univ Milan, Milan, Italy
[7] Natl Canc Ctr Hosp Japan East, Kashiwa, Chiba, Japan
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[10] Univ Munich, Munich, Germany
[11] Merck & Co Inc, Kenilworth, NJ USA
[12] Seagen Inc, Bothell, WA USA
[13] Sorbonne Univ, Paris, France
[14] Hop St Antoine, INSERM Instabil Microsatellites & Canc, Paris, France
[15] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS261
引用
收藏
页码：TPS261 / TPS261
页数：1
相关论文
共 50 条
  • [1] MOUNTAINEER-03: Phase III study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (trial in progress)
    Andre, T.
    Bekaii-Saab, T.
    Tabernero, J.
    Siena, S.
    Yoshino, T.
    Norwood, K. G.
    Adelberg, D. E.
    Ward, J.
    Yang, S.
    Strickler, J. H.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S734 - S735
  • [2] Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Heinemann, V.
    Bekaii-Saab, T.
    Van Cutsem, E.
    Tabernero, J.
    Siena, S.
    Yoshino, T.
    Nakamura, Y.
    Raghav, K.
    Cercek, A.
    Adelberg, D.
    Ramos, J.
    Yang, S.
    Andre, T.
    Strickler, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 159 - 160
  • [3] Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Fritsch, R.
    Andre, T.
    Bekaii-Saab, T.
    Cercek, A.
    Nakamura, Y.
    Raghav, K.
    Siena, S.
    Strickler, J.
    Van Cutsem, E.
    Adelberg, D.
    Ramos, J.
    Yang, S.
    Yoshino, T.
    Tabernero, J.
    SWISS MEDICAL WEEKLY, 2023, 153 : 70S - 70S
  • [4] Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Heinemann, Volker
    Andre, Thierry
    Bekaii-Saab, Tanios
    Cercek, Andrea
    Nakamura, Yoshiaki
    Raghav, Kanwal
    Siena, Salvatore
    Strickler, John
    Van Cutsem, Eric
    Adelberg, David
    Ramos, Jorge
    Yang, Shan
    Yoshino, Takayuki
    Tabernero, Josep
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 60 - 60
  • [5] MOUNTAINEER-03 phase III study design: first-line mFOLFOX6+tucatinib plus trastuzumab for HER2+metastatic colorectal cancer
    Strickler, John H.
    Bekaii-Saab, Tanios
    Cercek, Andrea
    Heinemann, Volker
    Nakamura, Yoshiaki
    Raghav, Kanwal
    Siena, Salvatore
    Tabernero, Josep
    Van Cutsem, Eric
    Yoshino, Takayuki
    Ramos, Jorge
    Guan, Xuesong
    Andre, Thierry
    FUTURE ONCOLOGY, 2025, 21 (03) : 303 - 311
  • [6] MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+metastatic colorectal cancer
    Bekaii-Saab, Tanios S.
    Van Cutsem, Eric
    Tabernero, Josep
    Siena, Salvatore
    Yoshino, Takayuki
    Nakamura, Yoshiaki
    Pratap Singh Raghav, Kanwal
    Cercek, Andrea
    Heinemann, Volker
    Adelberg, David E.
    Ramos, Jorge
    Yang, Shan
    Andre, Thierry
    Strickler, John H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer
    Belhadef, S.
    Arab, A.
    Belmadi, M.
    Beninal, M.
    Bacha, N.
    Abdallah, R.
    Mechta, K.
    Dahmane, A.
    Mahfouf, H.
    Oukkal, M.
    Bouzid, K.
    Faraqun, S.
    Bentabak, K.
    Younes, S. Ait
    ANNALS OF ONCOLOGY, 2020, 31 : S92 - S92
  • [8] A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+metastatic colorectal cancer (mCRC) (MOUNTAINEER).
    Strickler, John H.
    Niedzwiecki, Donna
    Zemla, Tyler
    Cercek, Andrea
    Fakih, Marwan
    Ng, Kimmie
    Sanchez, Federico Augusto
    Wu, Christina Sing-Ying
    Peterson, Scott
    Bandel, Lorelei
    Grothey, Axel
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Phase 3 study of maintenance treatment of tucatinib or placebo in combination with trastuzumab and pertuzumab in HER2+metastatic breast cancer (HER2CLIMB-05, trial in progress)
    Muller, V
    Hamilton, E.
    O 'Sullivan, C.
    Martin, M.
    Sohn, J.
    Tryfonidis, K.
    Santarpia, L.
    Yang, S.
    Dieras, V
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 106 - 106
  • [10] Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
    Strickler, J. H.
    Zemla, T.
    Ou, F-S.
    Cercek, A.
    Wu, C.
    Sanchez, F. A.
    Hubbard, J.
    Jaszewski, B.
    Bandel, L.
    Schweitzer, B.
    Niedzwiecki, D.
    Kemeny, N.
    Boland, P. M.
    Ng, K.
    Bekaii-Saab, T.
    ANNALS OF ONCOLOGY, 2019, 30
12345